-
Posted by
Two Blokes Jul 22 -
Filed in
Stock
-
6 views
SANTA ANA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present on the mechanism of action for troculeucel, enhanced non-genetically modified NK cell therapy, in Alzheimer's disease during a poster presentation at the upcoming Alzheimer's Association International Conference 2025 (“AAIC 2025”) to be held in Toronto, Canada and online from July 27-31, 2025.
